Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination.
Antibody
Diagnosis
Epitope, antigen conformation
Multiple sclerosis
Myelin oligodendrocyte glycoprotein
Optic neuritis
Journal
Acta neuropathologica communications
ISSN: 2051-5960
Titre abrégé: Acta Neuropathol Commun
Pays: England
ID NLM: 101610673
Informations de publication
Date de publication:
03 09 2019
03 09 2019
Historique:
received:
03
07
2019
accepted:
09
08
2019
entrez:
5
9
2019
pubmed:
5
9
2019
medline:
24
6
2020
Statut:
epublish
Résumé
Over recent years, human autoantibodies targeting myelin oligodendrocyte glycoprotein (MOG Ab) have been associated with monophasic and relapsing central nervous system demyelination involving the optic nerves, spinal cord, and brain. While the clinical relevance of MOG Ab detection is becoming increasingly clear as therapeutic and prognostic differences from multiple sclerosis are acknowledged, an in-depth characterization of human MOG Ab is required to answer key challenges in patient diagnosis, treatment, and prognosis. Herein, we investigated the epitope, binding sensitivity, and affinity of MOG Ab in a cohort of 139 and 148 MOG antibody-seropositive children and adults (n = 287 patients at baseline, 130 longitudinal samples, and 22 cerebrospinal fluid samples). MOG extracellular domain was also immobilized to determine the affinity of MOG Ab. MOG Ab response was of immunoglobulin G1 isotype, and was of peripheral rather than intrathecal origin. High affinity MOG Ab were detected in 15% paediatric and 18% adult sera. More than 75% of paediatric and adult MOG Ab targeted a dominant extracellular antigenic region around Proline42. MOG Ab titers fluctuated over the progression of disease, but affinity and reactivity to Proline42 remained stable. Adults with a relapsing course intrinsically presented with a reduced immunoreactivity to Proline42 and had a more diverse MOG Ab response, a feature that may be harnessed for predicting relapse. Higher titers of MOG Ab were observed in more severe phenotypes and during active disease, supporting the pathogenic role of MOG Ab. Loss of MOG Ab seropositivity was observed upon conformational changes to MOG, and this greatly impacted the sensitivity of the detection of relapsing disorders, largely considered as more severe. Careful consideration of the binding characteristics of autoantigens should be taken into account when detecting disease-relevant autoantibodies.
Identifiants
pubmed: 31481127
doi: 10.1186/s40478-019-0786-3
pii: 10.1186/s40478-019-0786-3
pmc: PMC6724269
doi:
Substances chimiques
Autoantibodies
0
Epitopes
0
MOG protein, human
0
Myelin-Oligodendrocyte Glycoprotein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
145Subventions
Organisme : National Health and Medical Research Council
ID : APP1142008
Pays : International
Organisme : Multiple Sclerosis Research Australia
ID : G173565
Pays : International
Organisme : Sydney Research Excellence Initiative 2020
ID : G201115
Pays : International
Investigateurs
Adriane Sinclair
(A)
Allan G Kermode
(AG)
Andrew Kornberg
(A)
Annie Bye
(A)
Benjamin McGettigan
(B)
Benjamin Trewin
(B)
Bruce Brew
(B)
Bruce Taylor
(B)
Chris Bundell
(C)
Christina Miteff
(C)
Christopher Troedson
(C)
Clair Pridmore
(C)
Claire Spooner
(C)
Con Yiannikas
(C)
Cullen O'Gorman
(C)
Damian Clark
(D)
Dan Suan
(D)
Dean Jones
(D)
Dean Kilfoyle
(D)
Deepak Gill
(D)
Denis Wakefield
(D)
Dirk Hofmann
(D)
Emily Mathey
(E)
Gina O'Grady
(G)
Hannah F Jones
(HF)
Heidi Beadnall
(H)
Helmut Butzkueven
(H)
Himanshu Joshi
(H)
Ian Andrews
(I)
Ian Sutton
(I)
Jennifer MacIntyre
(J)
Jennifer M Sandbach
(JM)
Jeremy Freeman
(J)
John King
(J)
John H O'Neill
(JH)
John Parratt
(J)
Joshua Barton
(J)
Justin Garber
(J)
Kate Ahmad
(K)
Kate Riney
(K)
Katherine Buzzard
(K)
Kavitha Kothur
(K)
Laurence C Cantrill
(LC)
Manoj P Menezes
(MP)
Mark A Paine
(MA)
Mark Marriot
(M)
Mahtab Ghadiri
(M)
Michael Boggild
(M)
Mitchell Lawlor
(M)
Monica Badve
(M)
Monique Ryan
(M)
Muhammed Aaqib
(M)
Neil Shuey
(N)
Nerissa Jordan
(N)
Nicholas Urriola
(N)
Nicholas Lawn
(N)
Owen White
(O)
Pamela McCombe
(P)
Rakesh Patel
(R)
Richard Leventer
(R)
Richard Webster
(R)
Robert Smith
(R)
Sachin Gupta
(S)
Shekeeb S Mohammad
(SS)
Sekhar Pillai
(S)
Simon Hawke
(S)
Sumu Simon
(S)
Sophie Calvert
(S)
Stefan Blum
(S)
Stephen Malone
(S)
Suzanne Hodgkinson
(S)
Tina K Nguyen
(TK)
Todd A Hardy
(TA)
Tomas Kalincik
(T)
Tyson Ware
(T)
Victor S C Fung
(VSC)
William Huynh
(W)
Références
Curr Treat Options Neurol. 2019 Jan 22;21(1):2
pubmed: 30671648
JAMA Neurol. 2018 Apr 1;75(4):478-487
pubmed: 29305608
J Vis Exp. 2013 Nov 23;(81):e50935
pubmed: 24300941
J Neuroinflammation. 2017 Oct 25;14(1):208
pubmed: 29070051
Ann Clin Transl Neurol. 2017 May 09;4(6):369-380
pubmed: 28589164
J Neuroimmunol. 2016 Feb 15;291:82-8
pubmed: 26857500
J Immunol. 1994 May 1;152(9):4489-99
pubmed: 8157964
Anal Chim Acta. 2010 Aug 31;676(1-2):60-7
pubmed: 20800743
Mult Scler. 2013 Sep;19(10):1261-7
pubmed: 23572237
Neurol Neuroimmunol Neuroinflamm. 2014 Oct 29;1(4):e40
pubmed: 25364774
J Neurol. 2016 Jul;263(7):1349-60
pubmed: 27147513
Neurol Neuroimmunol Neuroinflamm. 2015 Oct 15;2(6):e163
pubmed: 26516628
Acta Neuropathol Commun. 2015 Dec 04;3:82
pubmed: 26637322
Nat Med. 2007 Feb;13(2):211-7
pubmed: 17237795
Ther Adv Neurol Disord. 2018 Mar 29;11:1756286418762083
pubmed: 29623106
Neurology. 2011 Aug 9;77(6):580-8
pubmed: 21795651
Neurology. 2014 Dec 9;83(24):2219-26
pubmed: 25381299
Neurology. 2019 Mar 12;92(11):501-502
pubmed: 30728306
Brain. 2017 Dec 1;140(12):3128-3138
pubmed: 29136091
Front Immunol. 2018 Nov 29;9:2753
pubmed: 30555462
Eur J Neurol. 2018 May;25(5):782-786
pubmed: 29443442
J Histochem Cytochem. 2017 Jan;65(1):5-20
pubmed: 27798289
Am J Ophthalmol. 2018 Nov;195:8-15
pubmed: 30055153
Arch Immunol Ther Exp (Warsz). 2000;48(5):347-51
pubmed: 11140461
Bioconjug Chem. 2006 May-Jun;17(3):815-22
pubmed: 16704222
Ann Neurol. 2009 Dec;66(6):833-42
pubmed: 20033986
J Exp Med. 1999 Dec 6;190(11):1689-96
pubmed: 10587359
JCI Insight. 2017 Sep 7;2(17):
pubmed: 28878127
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):11059-64
pubmed: 12960396
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Brain. 2008 Jul;131(Pt 7):1940-52
pubmed: 18515870
Neurology. 2015 Jul 14;85(2):177-89
pubmed: 26092914
J Neuroinflammation. 2016 Jul 01;13(1):176
pubmed: 27371173
Neurol Neuroimmunol Neuroinflamm. 2015 Mar 19;2(3):e89
pubmed: 25821844
Neurol Neuroimmunol Neuroinflamm. 2015 Jan 22;2(1):e62
pubmed: 25635259
Neurol Neuroimmunol Neuroinflamm. 2014 May 22;1(1):e12
pubmed: 25340056
J Neurol. 2019 Apr;266(4):806-815
pubmed: 30607536
Neurology. 2019 Mar 12;92(11):e1250-e1255
pubmed: 30728305
Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8207-12
pubmed: 12060766
Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9446-51
pubmed: 12874380
Eur J Neurol. 2019 Aug;26(8):1137-e75
pubmed: 30748058
J Exp Med. 2009 Jun 8;206(6):1303-16
pubmed: 19487416
J Neuroimmunol. 1999 Jun 1;97(1-2):9-15
pubmed: 10408984
Neurol Neuroimmunol Neuroinflamm. 2016 Jun 30;3(5):e257
pubmed: 27458601
J Immunol Methods. 2006 Dec 20;317(1-2):80-9
pubmed: 17056057
J Mass Spectrom. 2008 Jun;43(6):699-715
pubmed: 18438963
Curr Opin Neurol. 2019 Jun;32(3):459-466
pubmed: 30762607
Case Rep Neurol Med. 2018 Dec 9;2018:1365175
pubmed: 30834146
Nat Rev Neurol. 2019 Feb;15(2):89-102
pubmed: 30559466
J Immunol. 2013 Oct 1;191(7):3594-604
pubmed: 24014878
Neurol Neuroimmunol Neuroinflamm. 2015 May 07;2(3):e104
pubmed: 25977932
Neurology. 2018 May 22;90(21):e1858-e1869
pubmed: 29695592
J Neuroinflammation. 2011 Nov 17;8:161
pubmed: 22093619
Neurology. 2014 Jul 8;83(2):142-50
pubmed: 24920861
Neurology. 2012 Sep 18;79(12):1273-7
pubmed: 22914827
J Neuroinflammation. 2016 Sep 26;13(1):279
pubmed: 27788675
Mult Scler. 1998 Jun;4(3):111-7
pubmed: 9762657
Curr Opin Neurol. 2019 Jun;32(3):313-319
pubmed: 30893100
Autoimmun Rev. 2016 Apr;15(4):307-24
pubmed: 26708342
J Neuroinflammation. 2016 Aug 30;13(1):219
pubmed: 27577085
Ann Neurol. 2018 Aug;84(2):315-328
pubmed: 30014603
J Neuroinflammation. 2018 May 3;15(1):134
pubmed: 29724224
J Neurosci Res. 1992 Sep;33(1):177-87
pubmed: 1453482
Eur J Immunol. 2004 Aug;34(8):2072-83
pubmed: 15259004
Mult Scler. 1998 Jun;4(3):99-107
pubmed: 9762655
J Neuroinflammation. 2015 Mar 08;12:46
pubmed: 25889963
Methods. 2015 Nov 1;89:91-8
pubmed: 25979347
Dev Med Child Neurol. 2019 May;61(5):610-614
pubmed: 30221764
Neurology. 2014 Feb 11;82(6):474-81
pubmed: 24415568
Neuropediatrics. 2018 Feb;49(1):3-11
pubmed: 28859212
IEEE/ACM Trans Comput Biol Bioinform. 2011 Nov-Dec;8(6):1483-94
pubmed: 21383422
J Neuroinflammation. 2019 Jul 2;16(1):134
pubmed: 31266527
J Biol Chem. 2012 May 18;287(21):17206-13
pubmed: 22493449
J Immunol. 2009 Sep 15;183(6):4067-76
pubmed: 19687098
J Neuroinflammation. 2016 Sep 27;13(1):280
pubmed: 27793206
J Neurol Neurosurg Psychiatry. 2018 Feb;89(2):127-137
pubmed: 29142145